How to Help Your Patients Save Money on Janumet: A Provider's Guide to Savings Programs

The Cost Problem with Janumet

Janumet (Sitagliptin/Metformin) is an effective, well-tolerated combination therapy for type 2 diabetes — but its price is a barrier for many patients. At $600-$750 for a 30-day supply without insurance, medication abandonment and non-adherence are real concerns.

No generic version of Janumet is currently available. The Sitagliptin patent expires in November 2026, but generic entry may not happen until late 2026 or 2027. In the meantime, your patients need help navigating the savings landscape.

This guide summarizes every available program and prescribing strategy to help your patients afford Janumet — organized for quick reference during clinical encounters.

Manufacturer Savings Programs (Merck)

Merck Savings Card for Janumet

Merck offers a copay savings card that reduces out-of-pocket costs for commercially insured patients:

• Eligible patients may pay as little as $5 per prescription
• Available at janumetxr.com/special-offers
• Card valid through the earlier of May 24, 2026 or the date a generic equivalent is approved
• Patients can enroll online, by phone, or through a provider enrollment form

Eligibility requirements:

• Must have commercial (private) insurance
• Not valid for patients with Medicare, Medicaid, Tricare, or other government insurance
• Patient must be 18 years or older

Provider action: Keep enrollment forms in your office or share the URL with patients at the point of prescribing. This is the single most impactful intervention for commercially insured patients.

Merck Helps Patient Assistance Program

For uninsured or underinsured patients who cannot afford Janumet:

• Provides Janumet free of charge to eligible patients
• Available at merckhelps.com
• Income-based eligibility (typically ≤400% of the federal poverty level)
• Requires provider signature and documentation of financial need
• Covers a 90-day supply, renewable

Provider action: If your patient is uninsured or their insurance doesn't cover Janumet, initiate the Merck Helps application. Your office staff can handle most of the paperwork — the key requirement is your signature confirming the clinical need.

Insurance Optimization Strategies

Formulary Navigation

Most commercial insurance plans cover Janumet as a Tier 3 (preferred brand) medication. Medicare Part D plans generally cover it as well. However, some plans may require:

• Prior authorization — demonstrating that Metformin alone was insufficient
• Step therapy — documented trial of Metformin monotherapy first
• Quantity limits — typically 60 tablets per 30 days (for immediate-release)

Provider tips for prior authorization:

• Document the patient's A1C on Metformin alone (showing inadequate control)
• Note any adherence benefits of combination therapy vs. separate pills
• Include any history of GI intolerance with higher Metformin doses that the combination helps mitigate
• Reference clinical guidelines supporting early combination therapy (ADA Standards of Care)

Appeal Strategies

If initial prior authorization is denied:

1. Request a peer-to-peer review with the plan's medical director
2. Cite ADA guidelines supporting DPP-4 inhibitor + Metformin combination
3. Document patient-specific factors (A1C trajectory, side effect history, adherence concerns)
4. Note that the combination tablet may improve adherence vs. separate medications

Third-Party Savings Resources

Prescription Discount Cards

For patients paying cash or with high-deductible plans, third-party discount cards can provide meaningful savings. While they won't match the Merck savings card for insured patients, they help uninsured patients who don't qualify for Merck Helps:

• GoodRx — widely accepted, shows prices by pharmacy
• SingleCare — often competitive pricing for brand medications
• RxSaver — compares multiple discount programs
• Optum Perks — integrated with many pharmacy systems

Note: Discount cards typically reduce the cash price by 10-30% for brand-name medications. For Janumet at $600-$750, this may still leave significant out-of-pocket costs. They work best as a supplement to other programs.

Patient Assistance Databases

Direct patients or your social work team to these resources for comprehensive program searches:

• NeedyMeds (needymeds.org) — database of patient assistance programs
• RxAssist (rxassist.org) — comprehensive directory of assistance programs
• RxHope (rxhope.com) — helps connect patients with manufacturer programs

Cost-Effective Prescribing Strategies

Consider Separate Components

If cost is the primary barrier, prescribing generic Metformin + brand Januvia (Sitagliptin) separately may be more affordable:

• Generic Metformin: approximately $4-$20/month
• Januvia (Sitagliptin alone): approximately $500-$600/month, but eligible for its own Merck savings card

The total may not be cheaper for the Sitagliptin component, but this approach gives flexibility — if the patient loses access to the savings card, at least the Metformin portion remains affordable.

Evaluate Alternative Combinations

If Janumet specifically is unaffordable, consider:

• Jentadueto (Linagliptin/Metformin) — Boehringer Ingelheim offers its own savings program. Doesn't require renal dose adjustment.
• Kombiglyze XR (Saxagliptin/Metformin ER) — AstraZeneca savings available. Once-daily dosing.
• Kazano (Alogliptin/Metformin) — Takeda may offer competitive pricing.

For clinical considerations when switching, see our patient-facing guide on alternatives to Janumet.

Janumet XR vs. Immediate-Release

Both formulations are priced similarly. However, Janumet XR (once daily) may improve adherence, which has downstream cost benefits — fewer ER visits, fewer complications, and better glycemic control. Consider switching patients who struggle with twice-daily dosing.

Medicare and Medicaid Patients

Patients with government insurance cannot use the Merck savings card. Options for these patients:

Medicare Part D

• Most Part D plans cover Janumet (check the plan's formulary)
• Patients may face donut hole costs — in 2026, the Inflation Reduction Act cap of $2,000/year on out-of-pocket Part D spending provides significant protection
• The Medicare Part D $2,000 cap means patients won't pay more than $2,000 total per year across all Part D medications — a major benefit for Janumet patients
• Encourage enrollment in Part D plans with favorable Janumet coverage during open enrollment

Medicaid

• Coverage varies by state, but most state Medicaid programs cover Janumet
• Prior authorization may be required
• Copays are typically minimal ($1-$4)

Extra Help (Low-Income Subsidy)

Medicare patients with limited income and resources may qualify for Extra Help, which significantly reduces Part D costs. Help patients apply through Social Security (ssa.gov) or their State Health Insurance Assistance Program (SHIP).

Workflow Integration

To make savings conversations efficient in clinical practice:

At Point of Prescribing

1. Check insurance formulary — confirm Janumet is covered and at what tier
2. Offer the Merck savings card for commercially insured patients
3. Initiate prior authorization if required (many EHRs automate this)
4. Discuss 90-day supply — lower per-unit cost and fewer pharmacy trips

For Uninsured Patients

1. Start the Merck Helps application at the visit
2. Refer to social work or financial counseling if available in your practice
3. Provide NeedyMeds/RxAssist information for additional resources
4. Consider prescribing generic Metformin immediately while the assistance application is processed (so the patient isn't waiting without treatment)

For Medicare Patients

1. Verify Part D coverage and confirm the plan's Janumet copay
2. Screen for Extra Help eligibility
3. Remind patients about the $2,000 annual cap on Part D out-of-pocket spending

Looking Ahead: Generic Janumet

The Sitagliptin patent expiration in November 2026 is a pivotal date. Once generic manufacturers enter the market:

• Prices could drop 70-90% within 1-2 years of generic entry
• Insurance coverage will likely shift to generic preferred
• Manufacturer savings programs for brand Janumet will likely end

For patients who can manage costs until then, the financial outlook improves significantly. For those who can't wait, the programs outlined above are essential bridges.

Provider Resources

For more clinical and practice management resources:

• MedFinder for Providers — tools to help patients find medication availability
• Janumet shortage: what providers need to know
• How to help patients find Janumet in stock

Medication cost shouldn't determine treatment decisions — but it often does. By proactively addressing affordability at the point of prescribing, you can improve adherence, outcomes, and patient trust.